Business
Taysha Gene Therapies Announces Participation in Upcoming March Investor Healthcare Conferences
Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 1:50 pm ET Stifel’s 3rd Annual CNS Day on Wednesday, March 31, 2021 at 10:30 am
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nOppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 1:50 pm ET\n\nStifel’s 3rd Annual CNS Day on Wednesday, March 31, 2021 at 10:30 am ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the Oppenheimer 31st Annual Healthcare Conference and Stifel’s 3rd Annual CNS Day.\n\nConferences Details:\n\nEvent: Oppenheimer 31st Annual Healthcare Conference (Virtual)\nDate: Tuesday, March 16, 2021\nTime: 1:50 pm ET\nFormat: Fireside chat\nParticipants: RA Session II, President, Founder and CEO\n\nEvent: Stifel’s 3rd Annual CNS Day (Virtual)\nDate: Wednesday, March 31, 2021\nTime: 10:30 am ET\nFormat: Fireside chat\nParticipants: RA Session II, President, Founder and CEO\n\nAudio webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies \n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210311005331/en/\n\nCompany Contact:\nKimberly Lee, D.O.\nSVP, Corporate Communications and Investor Relations\nTaysha Gene Therapies\[email protected]\n\nMedia Contact:\nCarolyn Hawley\nCanale Communications\[email protected]\n\nSource: Taysha Gene Therapies, Inc.","length":4421,"t...